Published February 3, 2018
| Version v1
Other
Open
Supplementary file Letter to Pharmaceutical companies in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies.
- 1. Psychiatric Research Unit, Region Zealand Psychiatry, Slagelse, Denmark
Description
Letter to pharmaceutical companies
Files
Brev medicinalfirmaer NRS review.pdf
Files
(173.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4ea996aa2f333816b8b52501742393e0
|
173.0 kB | Preview Download |